PCM
KRYS icon

Penserra Capital Management’s Krystal Biotech KRYS Stock Holding History

Penserra Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.91M Buy
+5,142
New +$1.54M 0.01% 372
2021
Q4 		– Sell
-510
Closed -$26K – 1461
2021
Q3 		$26K Buy
510
+5
+1% +$296 ﹤0.01% 1209
2021
Q2 		$34K Buy
505
+5
+1% +$349 ﹤0.01% 1077
2021
Q1 		$38K Buy
500
+50
+11% +$3.63K ﹤0.01% 861
2020
Q4 		$27K Buy
+450
New +$22.5K ﹤0.01% 809

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Penserra Capital Management's KRYS Position: Q2 2026 in Review

Penserra Capital Management opened a new position in Krystal Biotech (KRYS) in Q2 2026: 5,142 shares worth $1.91M. The stake represents 0.01% of the portfolio and ranks #372 among its holdings. This is a return to the name: Penserra Capital Management previously reported a position in KRYS as recently as Q3 2021.

Penserra Capital Management first reported a position in KRYS in Q4 2020 and has held it in 5 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Penserra Capital Management held 5,142 shares of Krystal Biotech worth $1.91M as of Q2 2026.
  • Krystal Biotech was a new Penserra Capital Management position in Q2 2026.
  • Krystal Biotech made up 0.01% of Penserra Capital Management's portfolio in Q2 2026, its #372 holding.
  • Penserra Capital Management first reported a position in Krystal Biotech in Q4 2020 and has held it in 5 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Penserra Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.